Two Sigma Securities’s Chinook Therapeutics, Inc. Common Stock KDNY Stock Holding History

Two Sigma Securities’s Portfolio KDNY Stock Details KDNY Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q3	–	Sell	-6,448	Closed	-$248K	–	3653
2023 Q2	$248K	Buy	+6,448	New	+$166K	﹤0.01%	2024
2022 Q2	–	Sell	-13,556	Closed	-$222K	–	2980
2022 Q1	$222K	Buy	+13,556	New	+$184K	0.01%	1668

Two Sigma Securities's KDNY Position: Q3 2023 in Review

Two Sigma Securities sold out of Chinook Therapeutics, Inc. Common Stock (KDNY) in Q3 2023, closing a stake of 6,448 shares — an estimated $248K sold.

Two Sigma Securities first reported a position in KDNY in Q1 2022 and held it in 2 quarters. The position peaked at $248K in Q2 2023. 2 funds tracked by Wall St. Rank hold KDNY as of Q3 2023.

Two Sigma Securities reported no remaining Chinook Therapeutics, Inc. Common Stock position as of Q3 2023 after selling out during the quarter.
Two Sigma Securities sold 6,448 Chinook Therapeutics, Inc. Common Stock shares in Q3 2023, an estimated $248K.
Two Sigma Securities first reported a position in Chinook Therapeutics, Inc. Common Stock in Q1 2022 and held it in 2 quarters.
Two Sigma Securities's Chinook Therapeutics, Inc. Common Stock position peaked at $248K in Q2 2023.
2 funds tracked by Wall St. Rank held Chinook Therapeutics, Inc. Common Stock as of Q3 2023.

Based on Two Sigma Securities's 13F filing for Q3 2023, filed 14 Nov 2023.